It wasn't the acquisition some investors had hoped for, but Acorda Therapeutics Inc. hardly could have asked for better terms in its ex-U.S. licensing deal for multiple sclerosis drug Fampridine-SR. (BioWorld Today)

With the PDUFA date for its capsaicin pain patch Qutenza (capsaicin 179 mg) rapidly approaching, NeurogesX Inc. gained a nice chunk of cash and squared away European rights to the product in a potential €105 million (US$145.5 million) deal with Astellas Pharma Inc. (BioWorld Today)

Adding itself to the short list of firms daring to brave the public markets this year, ImmunoGen Inc. aims to bolster its balance sheet with a public offering of 5 million shares priced at $7 each for $35 million in gross proceeds. (BioWorld Today)